FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
2873PDF: 803SUPPLEMENTARY MATERIAL: 270 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
184 -
PO:31:165 | Prevalence and incidence of skin telangectasia and their association with clinical features: analysis of the European Scleroderma Trials and Research cohort Gemma Lepri1, Lorenzo Tofani2, Silvia Bellando Randone1, Veronica Batani3, Paolo Airò4, Patricia Carreira5, Joerg Henes6, Alexandra Balbir Gurman7, Florenzo Iannone8, Antonella Marcoccia9, Luc Mouthon10, Branimir Anic11, Carolina De Souza Müller12, Armine Haroyan13, Ana Cristina Cordeiro14, Serena Guiducci And Eustar Coll1. | 1University of Florence, Dept of Experimental and Clinical Medicine, AOU Careggi, Division of Rheumatology Florence Italy; 2University of Florence, Dept of Statistics, Informatics, Applications, Florence, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, IRCCS San Raffaele, Milano, Italy; 4Scleroderma Unit, UOC Rheumatology and Clinical Immunology, ASST Spedali Civili, Brescia, Italy; 5Dept of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain; 6Centre for Interdisciplinary Rheumatology, Immunology and autoimmune diseases INDIRA, University Hospital Tuebingen, Tuebingen, Germany; 7Rheumatology Institute, Rambam Health Care Campus Haifa Israel; 8Dept of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy; 9Interdisciplinary Reference Center for Systemic Sclerosis CRIIS Sandro Pertini Hospital, Rome, Italy; 10Dept of Internal Medicine, Cochin Hospital, Paris Cité University, Paris, France; 11Div Clinical Immunology and Rheumatology, Dept Internal Medicine, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 12Rheumatology Division, Hospital de Clínicas da Universidade Federal do Parana, Curitiba, Brazil; 13Dept of Rheumatology, Yerevan State Medical University of Armenia, Yerevan, Armenia; 14Servico Reumatologia Hospital Garcia de Orta Almada, Almada, Portugal.
150 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
157 -
S13:5 | Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a European Scleroderma Trials and Research study Nicola Farina1, Silvia Bellando-Randone1, Sebastien Sanges2, Hilde Jenssen Bjørkekjær3, Lorenzo Tofani4, Marie-Elise Truchetet5, Vanessa Smith6, Andra Balanescu7, Christina Bergmann8, Yannick Allanore9, Philipp Klemm10, Simona Truglia11, Luca Idolazzi12, Christopher Denton13, Roberta Foti14, Anna Wojteczek15, Emmanuel Chatelus16, Madelon Vonk17, Serena Guiducci1, David Launay2, Eric Hachulla2, Jeska De Vries-Bouwstra18, Anna-Maria Hoffmann-Vold19, Oliver Distler20, Marco Matucci-Cerinic1, Cosimo Bruni1. | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az, Firenze, Italy; 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoi, Lille, France; 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway; 4Department of Statistics, Informatics and Applications, University of Florence, Firenze, Italy; 5Rheumatology department, CHU de Bordeaux, Bordeaux, France; 6University of Ghent, Department of Rheumatology, Gent, Belgium; 7Department of Rheumatology, St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy Bucharest Romania; 8Department Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany; 9Rheumatology Department, Université Paris Cité, Cochin Hospital, Paris, France; 10Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff Bad Nauheim Germany; 11Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy; 12Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy; 13Centre for Rheumatology, Royal Free London and University College London Medical School, London, United Kingdom; 14Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy; 15Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Univers Gdansk Poland; 16Department of Rheumatology, University Hospital Strasbourg Strasbourg France; 17Department of rheumatology, Radboud University Nijmegen Medical Center Nijmegen The Netherlands; 18Department of Rheumatology, Leiden University Medical Center Leiden The Netherlands; 19Department of Rheumatology, Oslo University Hospital, Oslo, Norway; 20Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
125 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
164 -
CO:09:6 | Risk of disease flare during pregnancy and postpartum in inflammatory arthritis: association with therapy discontinuation in the prospective P-RHEUM.it study Dina Zucchi1, Chiara Tani1, Francesca Crisafulli2, Alessia Gatti2, Maria Gerosa3, Cecilia Chighizola3, Melissa Padovan4, Salvatore D'Angelo5, Florenzo Iannone6, Maria Sole Chimenti7, Claudia Lomater8, Francesca Serale9, Veronique Ramoni10, Oscar Epis11, Bernd Raffeiner12, Ariela Hoxha13, Andrea Doria14, Leonardo Santo15, Valentina Canti16, Francesca Bellisai17, Giovanna Cuomo18, on behalf of the P-Rheumit Investigators19, Greta Carrara20, Cristina Di Nicola20, Davide Rozza20, Carlo Alberto Scirè20, Maria Chiara Gerardi11, Angela Tincani2, Laura Andreoli2, Marta Mosca1. | 1Rheumatology Unit, University of Pisa and Azienda Ospedaliero Universitaria Pisana; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia; 3Clinical Rheumatology Division, ASST Gaetano Pini-CTO and University of Milano; 4Rheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna and University of Ferrara; 5Rheumatology Department of Lucania - San Carlo Hospital, Potenza; 6Rheumatology Unit, DiMePRE-J, University of Bari; 7Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome-Tor Vergata, Roma; 8Torino Academic Rheumatology Center, A.O. Mauriziano di Torino, University of Torino; 9Rheumatology Unit, ASL CN1 Cuneo; 10Internal Medicine Department, ASST Lodi - Ospedale Maggiore di Lodi; 11Division of Rheumatology, Multispecialist Medical Department, Grande Ospedale Metropolitano Niguarda, Milano; 12Department of Rheumatology, Central Hospital of Bolzano SABES-ASDAA, Bolzano; 13General Medicine and Thrombosis and Hemorrhagic Unit, Department of Medicine, University of Padova; 14Rheumatology Unit, Department of Medicine, University of Padova; 15Rheumatology Unit, Mons. Dimiccoli Hospital, Barletta; 16Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano; 17Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena; 18Precision Medicine Department, University of Campania L. Vanvitelli, Napoli; 19The Italian Society for Rheumatology; 20Epidemiology Research Unit of the Italian Society for Rheumatology, Milano, Italy
151 -
CO:01:4 | Identify predictors of relapse in idiopathic inflammatory myopathies: insights from an international cohort Cristina Bochicchio1|2, Maria Rosa Pellico1|2, Claudia Iannone1|2, Lekshmi Minikumari Rahulan3, Marco Fornaro4, Ilaria Cavazzana5, Edoardo Conticini6, Musataka Musataka7, Akira Yoshida7, Silvia Cavalli1|2, Silvia Grazzini6, Giulio Fraticelli8, Alessia Gatti5, Giulio Lopinto4, Paolo Semeraro5, Veronica Batani8, Thomas Patric Sheeran9, Florenzo Iannone4, Giacomo De Luca8, Roberto Caporali1|2, Latika Gupta9|10|11, Nicoletta Del Papa2. | 1Department of Clinical Sciences and Community Health, University of Milano; 2Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO Institute, Milano, Italy; 3Rheumatology "Sanjay Gandhi" Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; 4Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica, University of Bari; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili di Brescia; 6Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy; 7Department of Allergy and Rheumatology Nippon Medical School Graduate School of Medicine, Tokyo, Japan; 8Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano, Italy; 9Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK; 10Francis Crick Institute, London, UK; 11School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, UK
195 -
PO:33:199 | Prevalence and clinical associations of antiphospholipid antibodies in patients with systemic sclerosis in the SPRING-SIR registry Antonio Tonutti1|2, Ilaria Cavazzana3, Angela Ceribelli1|2, Maria De Santis1|2, Giacomo De Luca4|5, Maria Grazia Lazzaroni3, Franco Franceschini3, Carlo Selmi1|2, Valeria Riccieri6, Silvia Laura Bosello7, Fabio Cacciapaglia8, Veronica Codullo9, Francesca Ingegnoli10, Dilia Giuggioli11, Rossella De Angelis12, Clodoveo Ferri11, Marco Matucci-Cerinic4|5 | 1Department of Biomedical Sciences, Humanitas Universityce Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Rheumatology and Clinical Immunology - ASST Spedali Civili Brescia - Department of Clinical and Experimental Sciences - Brescia, Italy; 4Vita-Salute San Raffaele University Milan, Italy; 5Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR and INFLAGE Initiative, IRCCS San Raffaele Hospital Milan, Italy; 6University of Rome La Sapienza Rome, Italy; 7Catholic University of Sacred Heart Rome, Italy; 8LUM University Bari, Italy; 9Rheumatology Unit, Fondazione IRCCS Policlinico San Matteo Pavia, Italy; 10University of Milan Milan, Italy; 11University of Modena and Reggio Emilia Modena, Italy; 12Politechnic University of Marche Ancona, Italy
17 -
CO:08:5 | Clinical impact of anti-Ro52 antibodies in idiopathic inflammatory myopathies: insights from a multicenter Italian cohort Paola Bizioli1, Cesare Tomasi2, Francesca Bellisai3, Francesca Buzzulini4, Antonio Tonutti5|6, Angela Ceribelli5|6, Edoardo Conticini3, Anna Ghirardello7, Luca Iaccarino7, Danilo Villalta4, Franco Franceschini1, Ilaria Cavazzana1. | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia; 2Department of Clinical and Experimental Sciences, University of Brescia; 3Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena; 4Department of Laboratory Immunology and Allergology, Santa Maria degli Angeli Hospital, Pordenone; 5Department of Biomedical Sciences, Humanitas University, Rozzano (MI); 6Rheumatology and Clinical Immunology, Istituti di Ricovero e Cura a Carattere Scientifico, Humanitas Research Hospital, Rozzano (MI); 7Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padova, Italy
138 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
43 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
193 -
PO:06:079 | Weighing the burden: how body mass index shapes clinical outcomes in rheumatoid arthritis. Insights from a large Italian cohort Marco Capodiferro1, Marco Fornaro1, Gian Luca Erre2, Matteo Piga3, Elena Bartoloni Bocci4, Andreina Manfredi5, Ennio Giulio Favalli6, Maria Sole Chimenti7, Serena Guiducci8, Eleonora Celletti9, Addolorata Corrado10, Alessandro Giollo11, Simone Parisi12, Ivan Giovannini13, Elisa Gremese14, Garifallia Sakellariou15, Ombretta Viapiana16, Fabiola Atzeni17, Francesca Romana Spinelli18, Fabio Cacciapaglia1|19. | 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area DiMePRe-J University of Bari, Bari, Italy; 2Dipartimento di Scienze Mediche, Chirurgiche e Sperimentali, Università degli Studi di Sassari, Sassari, Italy; 3Rheumatology Unit, AOU Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; 4Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 5Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, Modena, Italy; 6Dpt of Rheumatology, G. Pini Institute, Milano, Italy; 7Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; 8Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy; 9Rheumatology Unit, SS Annunziata Hospital, Chieti, Italy; 10Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 11Rheumatology Unit, Department of Medicine, University of Padova Hospital Trust, Padova, Italy; 12Rheumatology Department, A.O.U. Città della Salute e della Scienza, Torino, Italy; 13Rheumatology Department, Santa Maria della Misericordia Hospital, Udine, Italy; 14Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy; 15Department of Internal Medicine and Therapeutics, University of Pavia, Istituti Clinici Scientifici Maugeri, Pavia, Italy; 16Rheumatology Unit, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy; 17Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy; 18Reumatology Unit, Department of Internal, Anesthesiological, and Cardiovascular Clinical Sciences, Sapienza University, Roma, Italy; 19Miulli General Hospital Acquaviva - Department of Medicine and Surgery, LUM F. De Gennaro University, Casamassima (BA), Acquaviva delle Fonti (BA), Italy.
164 -
The diagnostic utility of miRNA21 in systemic sclerosis
992PDF: 124SUPPLEMENTARY MATERIAL: 33 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
45 -
PO:32:178 | Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study Nicola Farina1, Silvia Bellando-Randone1, Hilde Jenssen-Bjørkekjær2, David Launay3, Patricia Carreira4, Paolo Airò5, Serena Guiducci1, Dilia Giuggioli6, Gabriela Riemekasten7, Carmen-Pilar Simeón Aznar8, Christina Bergmann9, Elise Siegart10, Ivan Castellví11, Lesley Ann Saketkoo12, Jeska De Vries-Bouwstra13, Philipp Klemm14, Ulf Müller-Ladner14, Alexandra Balbir-Gurman15, Vanessa Smith16, Florenzo Iannone17, Luca Idolazzi18, Christopher Denton19, Edoardo Rosato20, Britta Maurer1, Yannick Allanore1, Yoshiya Tanaka1, Elisabetta Zanatta1, Oliver Distler1, Marco Matucci-Cerinic1, Cosimo Bruni1 | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az Firenze, Italy; 2Department of Rheumatology, Hospital of Southern Norway Kristiansand, Norway; 3National Reference Center for Pulmonary Arterial Hypertension Pulmotension Lille, France; 4Hospital Universitario 12 de Octubre, Rheumatology Department Madrid Spain; 5ASST Spedali Civili of Brescia, University of Brescia, Rheumatology and Clinical Immunology Unit Brescia, Italy; 6Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia Modena, Italy; 7Universitätsklinikum Schleswig-Holstein, Klinik für Rheumatologie und klinische Immunologie Lübeck Germany; 8Hospital Universitario Vall d'Hebron, Department of Internal Medicine, Systemic Autoimmune Diseases Unit Barcelona Spain; 9University Hospital Erlangen, Department Internal Medicine 3 Erlangen Germany; 10Charité University Hospital, Department of Rheumatology Berlin Germany; 11Hospital de la Santa Creu i Sant Pau Baercelona Spain; 12New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center New Orleans, USA; 13Leiden University Medical Center, Department of Rheumatology Leiden, The Netherlands; 14JLU Giessen, Campus Kerckhoff, Department of Rheumatology and Clinical Immunology Center Bad Nauheim Germany; 15Rambam Health Care Campus, Rheumatology Institute Haifa, Israel; 16University of Ghent, Department of Rheumatology Ghent, Belgium; 17Rheumatology DiMePReJ, University of Bari, School of Medicine Bari, Italy; 18University of Verona, Section of Rheumatology, Department of Medicine Verona, Italy; 19Royal Free London and University College London Medical School, Centre for Rheumatology London, United Kingdom; 20Sapienza University of Rome, Department of Translational and Precision Medicine Azienda Ospedaliero-Universitaria Policl Roma, Italy
16
